Patient Experiences and Considerations for Axatilimab Therapy in Steroid-Refractory cGVHD
Panelists discuss how axatilimab demonstrates particularly good responses for gastrointestinal graft-vs-host disease (GVHD) and may improve sclerotic skin changes despite lower rates of overall skin response.
Clinical Experience with Newer Agents
The final segment covers the panelists’ perspectives on the AGAVE-201 trial data and early clinical experience with axatilimab. They note:
- Strong efficacy in gastrointestinal manifestations of chronic GVHD
- Efficacy in heavily pretreated patients (85% had prior ruxolitinib/ibrutinib/belumosudil)
- Different mechanism of action provides new options for refractory disease
- Early clinical experience shows good tolerability
- Potential adverse events to monitor: liver enzyme elevations, infusion reactions, periorbital edema
The panel discusses the practical aspects of intravenous administration (every 2 weeks) and their approaches to sequential vs combination therapy. Most prefer to add axatilimab while maintaining current therapy, then gradually tapering prior agents, though practices vary between centers.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
